Pharvaris, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Maxwell Skor from Morgan Stanley maintained a Buy rating on the stock and has a $34.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Maxwell Skor has given his Buy rating due to a combination of factors surrounding Pharvaris’s recent developments. The company has accelerated the timeline for the release of topline data from its pivotal Phase 3 RAPIDe-3 trial for deucrictibant, which is now expected in the fourth quarter of 2025, earlier than the previously anticipated first quarter of 2026. This advancement is attributed to a faster-than-expected accrual of attacks in the study, which could lead to an earlier submission of a New Drug Application in the first half of 2026.
Skor is optimistic about the potential of deucrictibant to deliver efficacy comparable to injections for both on-demand and prophylactic treatment of hereditary angioedema (HAE). Additionally, the recent FDA approval of KalVista’s Ekterly, the first oral on-demand treatment for HAE, highlights the market’s readiness for innovative oral treatments. Skor plans to monitor the launch of Ekterly to understand patient dynamics and the potential market impact, which could further inform the investment outlook for Pharvaris.
According to TipRanks, Skor is an analyst with an average return of -3.6% and a 44.44% success rate. Skor covers the Healthcare sector, focusing on stocks such as Pharvaris, Cytokinetics, and Insmed.
In another report released yesterday, JonesTrading also reiterated a Buy rating on the stock with a $43.00 price target.